Drug Trial Radar · NCT03816163
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
393
Actual
Start
Mar 15, 2019
Primary completion
Oct 31, 2026
Study completion Oct 31, 2026
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's immune system to attack the tumor. Zolbetuximab is a potential treatment for people with pancreatic cancer. There is an unmet medical need to treat people with pancreatic cancer. This study will help find the dose of zolbetuximab to be used with chemotherapy and provide more information on this treatment in adults with metastatic pancreatic cancer. The study is currently ongoing globally. People in this study will be treated with either zolbetuximab and chemotherapy or chemotherapy by itself. The study's main aims are to find a suitable dose of zolbetuximab to be used with chemotherapy in the second part of this study, to check if zolbetuximab and chemotherapy compared to chemotherapy by itself can improve the survival of people with pancreatic cancer, and to check the safety of zolbetuximab when given with chemotherapy and how well people cope with medical problems during the study. Adults with metastatic pancreatic cancer can take part. Their cancer is metastatic, has the CLDN18.2 marker in a tumor sample and has not previously been treated with chemotherapy. Metastatic means the cancer has spread to other parts of the body. People cannot take part are if they have recently had radiotherapy and have not recovered, need to take medicines to suppress their immune system, have history of nervous system metastases from their pancreatic cancer, or they have other active cancers that need treatment. People who have a specific heart condition or infections also cannot take part. This study will be in 2 parts. Part 1 is called the Safety Lead-in Phase. Groups of people will receive 1 of 2 different doses of zolbetuximab: a lower dose or a higher dose, both together with chemotherapy. A medical expert panel will check the results and decide the dose to use in Part 2. Part 2 is called the Randomization Phase. People will be put in 1 of 2 groups by chance and will be given different treatments either zolbetuximab and chemotherapy or chemotherapy by itself. The chance of receiving zolbetuximab and chemotherapy is twice as high as receiving chemotherapy by itself. In both parts of the study, zolbetuximab and chemotherapy or chemotherapy by itself will be given through a vein. This is called an infusion. Each treatment cycle is 4 weeks (28 days) long and people will have either 2 infusions of zolbetuximab and 3 infusions of chemotherapy or 3 infusions of chemotherapy by itself during each treatment cycle. People will visit the clinic on certain days during their treatment. The study doctors will check for any medical problems from zolbetuximab. Also, people in the study will have a health check including blood tests. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken before treatment if a previous sample is not available. People will have the option of giving a tumor sample after treatment has finished. People will visit the clinic after they stop treatment. They will be asked about any medical problems and will have a health check including blood tests. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not. Astellas is terminating the zolbetuximab pancreatic development program from Dec 2025 (following the final OS analysis in Oct 2025). Active subjects may remain on treatment if the investigator determines they are receiving benefit from it. The Survival follow-up period is no longer required.
Conditions
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma
Interventions
zolbetuximabDrug
Administered as an intravenous infusion.
nab-paclitaxelDrug
Administered as an intravenous infusion
gemcitabineDrug
Administered as an intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT) - (safety lead in)Time frame: Up to 28 days
- Overall Survival (OS)Time frame: Up to 79 months
- Safety assessed by Adverse Events (AEs)Time frame: From signing inform consent form until 90 days after the last dose of the study drug (Up to 82 months)
- Safety assessed by incidence of serious adverse events (SAE)Time frame: From signing inform consent form until 90 days after the last dose of the study drug (Up to 82 months)
- Safety assessed by incidence of treatment emergent adverse events (TEAE)Time frame: From first dose up to 30 days after last dose (Up to 80 months)
- Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: From first dose up to 30 days after last dose (Up to 80 months)
- Number of participants with vital sign abnormalities and /or adverse events (AEs)Time frame: From first dose up to 30 days after last dose (Up to 80 months)
- Number of participants with electrocardiograms (ECG) abnormalities and or adverse eventsTime frame: From first dose up to 30 days after last dose (Up to 80 months)
- Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse eventsTime frame: From first dose up to 30 days after last dose (Up to 80 months)
Locations
136 sites in 13 countries. Site status is shown where the registry gives one.
St. Joseph Heritage Medical Group
Fullerton, California
TOI Clinical research
Whittier, California
Midstate Medical Center
Meriden, Connecticut
Lynn Cancer Institute
Boca Raton, Florida
Baptist Health
Miami, Florida
Cancer Treatment Centers of Atlanta
Newnan, Georgia
University of Illinois at Chicago
Chicago, Illinois
Norton Cancer Institute (NCI)
Louisville, Kentucky
Ochsner Health System
New Orleans, Louisiana
David C Pratt Cancer Center
Creve Coeur, Missouri
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen
Montvale, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Commack
Commack, New York
Memorial Sloan Kettering Westchester
Harrison, New York
Northwell Health Cancer Institute
Lake Success, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Memorial Sloan Kettering Nassau
Uniondale, New York
Novant Health Presbyterian Medical Center
Charlotte, North Carolina
Novant Health
Winston-Salem, North Carolina
Houston Methodist Hospital
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
MultiCare Regional Cancer Center - Gig Harbor
Gig Harbor, Washington
Vista Oncology
Olympia, Washington
Virginia Mason
Seattle, Washington
Site AU61008
Gosford, New South Wales, Australia
Site AU61007
Wollongong, New South Wales, Australia
Site AU61005
Fitzroy, Victoria, Australia
Site AU61006
Warrnambool, Victoria, Australia
Site BR55009
Centro Passo Fundo, Brazil
Site BR55008
Rio Grande, Brazil
Site BR55004
Santa Catarina, Brazil
Site BR55010
São Paulo, Brazil
Site BR55011
São Paulo, Brazil
Site BR55012
Porto Alegre, Rio Grande do Sul, Brazil
Site CN86001
Beijing, China
Site CN86008
Beijing, China
Site CN86014
Beijing, China
Site CN86026
Changchun, China
Site CN86009
Chongqing, China
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.